reason report
strong sale driven adopt momentum
bottom line today market close report strong
beat first full quarter launch sale came
y/i ahead street ahead us
ahead believ buy side expect
out-performance broad-bas intern
beat expect driven continu momentum new patient
add notabl sale grew even absorb point
headwind well-telegraph price pressur start
come fruition note manag previous guid
point price headwind cover live
cover pharmaci channel adopt momentum
come even competit ramp mp libr also continu
grow strong double-digit impli midst
adopt inflect cgm continu glucos monitor overal
quarter beat -- cgm market overal --
driven continu product innov also increas
awar around cgm manufactur increas invest
market campaign believ now-high
-- come beat impli new patient
add momentum continu remaind year
guidanc also factor believ base-cas --
even borderlin bear-cas -- scenario price new
patient add perspect reflect point headwind
vs around price competit either may transpir
may off-set volum launch one
meaning product iter ever even estim like
move meaning higher follow report continu
believ uncertainti tie competit price leav
ampl room upsid year next year
reiter op rate pt pt appli ev/sal
sale estim share current trade
sale estim premium compar
nxtm believ continu
deliv estim upsid sustain ev/sal multipl current
level ultim believ share warrant least modest
premium small-cap med-tech stock univers given
massiv highli under-penetrated total address market
per estim consist upsid potenti top-tier
medic suppli devic
sale
compani inform leerink partner llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
outlook higher sale
estim move higher y/i y/i
respect
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea --
essenti cgm-augment insulin pump system automat accur dose
patient new patient adopt momentum -- launch -- like
sustain sale growth near medium term despit competit headwind continu
product evolut includ possibl much less-costli type product conjunct
googl partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share current trade
sale estim premium compar small-cap med-tech
compani nxtm believ
continu deliv estim upsid sustain ev/sal multipl current level
ultim believ share warrant least modest premium small-cap
med-tech stock univers given substanti highli under-penetrated total
address market per estim consist upsid potenti top-tier
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
research develop expens
incom equiti invest
sg sale
 sale
oper expens sale
compani report leerink partner estim
partnership verili formerli googl life scienc
develop bandage-lik sensor togeth data analyt
address non-insulin-us type market sensor
label day
miniatur dispos bandage-lik sensor size
studi compar glycem qualiti life benefit
monitor cgm self-monitor blood glucos smbg
made studi particip primari care physician
decis base insight real-tim use
retrospect insight determin remot visit
studi assess patient type diabet
sub-optimal glycem control use multipl oral agent
abl make lifestyl chang result improv
glycem control use real-tim continu glucos
monitor rt-cgm target learn modul versu
complet trial complet
feb acceler effort verili expect complet
develop
time depend calibr
feb initi feasibl studi complet
on-go plan enrol patient
prospect random multicent two-arm confirmatori studi plan enrol
increas includ increment
spend on-intens
spend on-intens program
spend on-intens program
spend on-intens program
low-end
end
end
end
